Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.

View in: PubMed

subject areas

Adalimumab
Adult
Antibodies, Monoclonal, Humanized
Biological Products
Colitis, Ulcerative
Colorectal Neoplasms
Crohn Disease
Female
Gastrointestinal Agents
Hospitalization
Humans
Inflammatory Bowel Diseases
Infliximab
Male
Middle Aged
Retrospective Studies
Ustekinumab

authors with profiles

David Rubin